The primary objective of the PGL.EXPO-2 study is to test the hypothesis that exposure (occupational, environmental and/or domestic) to succinate dehydrogenase inhibitors (SDHi) could contribute to tumor emergence in subjects carrying a germline mutation in one of the SDHx genes.The primary endpoint will be the proportion of subjects (cases or controls) exposed to SDHi and the association with paraganglioma risk.
In addition, a blood sample (10 ml on EDTA) will be proposed to the participants to the study
Cases: SDHx mutation carriers diagnosed for a SDHx-related tumor
Controls: SDHx mutation carriers with no SDHx-related tumor
Incapacity to exercise free and informed consent for the study
Patient under tutorship or guardianship or legal safeguard
Assistance Publique - Hôpitaux de Paris
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Collaborator
ANSES
Collaborator
Centre Leon Berard
Collaborator